Lung Cancer
About Lung Cancer
Lung cancer is the second most common cause of death among women. A recent trend show that Lung cancer becomes biggest killer of Australian women.
Reducing Lung cancer risk
A diverse diet of fruits and vegetables may decrease the risk of lung cancer - especially if you smoke.
Lung cancer market
Decision Resources, a research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013.
Recent research on Lung cancer
- New research at Temple University - Stereotactic body radiotherapy technique (SBRT) that improves a person's odds of surviving early stage Lung cancer and also reduce the need for future surgeries
Victims of Lung cancer
- Actress Patricia Neal died from lung cancer in August 2010, at the age of 84.
- Disco legend Donna Summer, passed away in 2012
- Revered soul guitarist, Charles 'Skip' Pitts, in 2012
Celebrities diagnosed with Lung Cancer
Tony Greig
Former England Cricket captain Tony Greig is diagnosed with lung cancer in October 2012. Greig will undergo a surgery to find the extent of the disease. He was initially diagnosed with bronchitis in May 2012. "I have had a few scrapes in my life and this is another one. Vivian and I are going to put the boxing gloves on and fight this like we've never fought anything before.", he said.
Tony Greig will have an operation in the third week of November 2012. He was absent in the commentary box on the first cricket test between Australia and South Africa on 9 November 2012. He is having tests which confirmed the necessity for an operation. Greig's old adversary Dennis Lillee spoke to Greig on phone which was said to have lifted the spirits of Greig.
Other information
- Australians are the world's least sympathetic when it comes to patients diagnosed with lung cancer.
Lung Cancer in News
NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the ASCO 2013 Annual Meeting
NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced that several clinical presentations on its two proprietary platform technologies have been selected for the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held May 31 to June 4, 2013 in Chicago, IL
Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual Meeting
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced the presentation of three clinical posters at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 31-June 4, 2013 in Chicago, Illinois.
Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual Meeting
Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets, Kyprolis® (carfilzomib) for Injection, and Stivarga® (regorafenib) tablets across a range of cancers
IsoRay, Inc. Reports Third Quarter Results
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic ("gyn") cancer, announced its financial results for the quarter and nine months ended March 31, 2013.
NewLink Genetics Corporation Reports First Quarter 2013 Financial Results
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapies to improve treatment options for patients with cancer, today reported consolidated financial results for the first quarter of 2013.
Overall U.S. Costs of Cancer to Spike to $158 Billion by 2020
TriMark Publications (http://www.trimarkpublications.com), a global leader in biotechnology, healthcare and life sciences publishing, announces the release of its Cancer Diagnostic Testing report. Cancer diagnostic testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment
Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab
Picomole Announces the Development of Non-Invasive Breath Test for Lung Cancer
Picomole Inc. ("Picomole"), the world leader in infrared technologies for breath analysis, announced today that it has developed a diagnostic test to detect lung cancer that has a preliminary accuracy of 98.5%. This best-in-class result is better than any other technique currently in use for the detection of lung cancer.
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Novartis International AG /Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.
Data Presented at AACR Annual Meeting Support Targeted Immune Reactivation Mechanism and Potential of Peregrine's Bavituximab in Solid Tumor Therapy
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today highlighted data presented at the Annual Meeting of the American Association for Cancer Research (AACR)
Eisai Announces Preclinical Research Findings Suggesting Novel Infibitory Effect on Tumor Metastasis for Anticancer Agent Halaven(R) at AACR 104th Annual Meeting
Eisai Co., Ltd. announced today that it has presented preclinical research findings suggesting a potential inhibitory effect on tumor metastasis as a possible novel mechanism of action for anticancer agent Halaven(R) (eribulin mesylate, "eribulin") at the American Association for Cancer Research (AACR) 104th Annual Meeting ("AACR 2013")
Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announces that it has completed several new IND-Enabling studies, including one in which the cytotoxic activity of Adva-27a, the Company's flagship oncology drug candidate, was measured in the HMEC cell line
Helix Biopharma Corp. Initiates Enrollment for Third Cohort and Expansion of Centres in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the third dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland
Leading U.S. Pulmonologists to Investigate Impact of Mauna Kea Technologies' Cellvizio on Lung Cancer Diagnosis
Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, announced today that it has launched a registry study to determine the impact of Cellvizio optical biopsies on the diagnosis of lung cancer, the leading cause of cancer death in the world
Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
Novartis International AG /Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.
Journal of Immunology Research: Vaccine Based Upon Heat Biologics' ImPACT Therapy Provides Significant Protection Against SIV Infection
Research published in the current issue of Journal of Immunology demonstrates that a vaccine based upon Heat Biologics' ImPACT technology provides significant protection against the Simian Immunodeficiency Virus (SIV), a non-human virus closely related to the HIV virus that causes AIDS
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the third quarter ended January 31, 2013 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.
Integrated Diagnostics(R) Appoints CFO & VP Sales Prior to Launch of Lung Cancer Diagnostic
Integrated Diagnostics (Indi®), an emerging leader in molecular diagnostics, today announced that it has appointed John Bencich as chief financial officer and Jill Tonachio as vice president for sales. The two executives will play key roles in the launch of the company's first commercial product later this year, a blood test for the early diagnosis of lung cancer
University of Louisville Recognized as Entrepreneurial Champion for Third Consecutive Year at University of Cincinnati Spirit of Enterprise Competition Hosted by Cincom
Four medical diagnostic entrepreneurs from the University of Louisville were awarded $10,000 by Cincom CEO, Tom Nies (http://tomnies.cincom.com), for their non-invasive screening tool that captures volatile organic compounds (VOCs) from a patient's breath to accurately detect lung cancer
ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC
For non U.S. Media Only
Clinical Update: Helix BioPharma Corp. Completes Enrollment in First Cohort and Initiates Second Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announced the opening of patient screening for the second dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland
Equity Brief: Ratings Changes for December 20th: SASR, SD, SGY, SLGN, SNSS, ST, STN, TAP
A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:
Viratech Announces Acquisition of Cancer.im for $6.2 Million in Securities
Viratech Corp. (PINKSHEETS: VIRA) http://viratech.org, the first open source biotech research social network platform, announced today an acquisition merger with Cancer.im, Inc., in exchange for $6.2 million in Viratech restricted common stock.
Market for Kinase Inhibitors Heats Up: Kalorama
The cancer kinase inhibitor market is estimated at $12.1 billion worldwide for 2012, representing annual revenue growth of 16.9% over 2007. The effectiveness of kinase inhibitors has sparked interest from major pharmaceutical companies, according to the healthcare market research publisher, Kalorama Information
Near Term Catalyst Has ArQule Poised for a Move Up
ArQule, Inc. engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes.
ArQule (ARQL) Poised For A Quick Move Up On Near Term Catalyst
By Scott Matusow, Contributor@scottmatusow
A Strong Speculative BioPharma Poised For A Quick Move Up On Near Term Catalyst
By Scott Matusow, Contributor@scottmatusow
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter ended October 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.
Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found to Be Effective Against Multidrug Resistant Uterine Cancer Cells
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate, was found to be effective at killing Multidrug Resistant Uterine Cancer Cells in vitro
Helix BioPharma Corp. Announces Sale of Rivex Pharma Division to Pharmascience Inc.
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive agreement for the sale of its Rivex Pharma division to Pharmascience Inc. ("Pharmascience") for gross cash proceeds of up to $8.5 million (the "Rivex Transaction")
Sunshine Biopharma Completes Six IND-Enabling Studies for Its Anticancer Compound, Adva-27a
Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed six IND-Enabling studies for Adva-27a, the Company's flagship oncology drug candidate
Laughlin Constable and Wisconsin Department of Tourism to Bring Widen Digital Asset Management Into Their Communications Workflows
Widen Enterprises, a Madison-based provider of digital asset management solutions (Widen Media Collective), has been chosen by Laughlin Constable to meet the agency's DAM software needs in serving the Wisconsin Department of Tourism.
Cambridge Heart Reports Results for the Three and Nine Months Ended September 30, 2012
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today reported results for the three and nine months ended September 30, 2012. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which will be filed with the Securities and Exchange Commission on November 14, 2012.
IsoRay, Inc. Reports First Quarter Results
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gyn cancer announced its financial results for the quarter ended September 30, 2012.
Picomole Granted U.S. Patent for its Breath Analysis Technology
Picomole Instruments Inc., the world leader in infrared technologies for breath analysis, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,288,727 entitled "Apparatus and method for rapid and accurate quantification of an unknown, complex mix".
Sunshine Biopharma Initiates IND-Enabling Studies for Its Anticancer Compound, Adva-27a
Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the IND-Enabling studies for Adva-27a, the Company's flagship oncology drug candidate
Scientists and Clinicians Collaborate on 8 Projects to Better Understand and Treat Diseases Prevalent in Asia
Singapore announces 8 biomedical sciences research programmes to advance understanding and treatment of diseases especially prevalent amongst the Asian population. These programmes will see biomedical scientists and clinicians working collaboratively to bring about greater healthcare benefits to society and create economic growth for Singapore
Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds
Novartis International AG /Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.
Holzer Holzer & Fistel, LLC Has Filed a Class Action Lawsuit on Behalf of Investors in Peregrine Pharmaceuticals, Inc.; Reminds Investors With Large Losses of November 27th Lead Plaintiff Deadline
Holzer Holzer & Fistel, LLC has filed a class action lawsuit in the United States District Court for the Central District of California on behalf of purchasers of Peregrine Pharmaceuticals, Inc. ("Peregrine" or the "Company") (NASDAQ: PPHM) common stock who purchased shares between August 30, 2012 and September 26, 2012, inclusive (the "Class Period")
Beach Boys reuniting to mark golden anniversary in 2012
The surviving members of band 'The Beach Boys' are planning to reunite in 2012 to celebrate their golden anniversary year, commemorating their first important record deal with the Capitol label.
Peregrine Provides Update on HCV Clinical Program
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus (HCV)
Axelar initiates a Phase II clinical study with AXL1717 for the treatment of non-small cell lung cancer
STOCKHOLM, SWEDEN - December 28, 2011. Axelar AB, a Karolinska Development AB portfolio company, today announces that the first patient has been dosed in a randomized Phase II study on non-small cell lung cancer (NSCLC) patients of its drug candidate AXL1717
Verisante Starts FDA Approval Process and Provides Operational Update
Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF)(PINKSHEETS: VRSEF)(FRANKFURT: V3T) (the "Company" or "Verisante"), a leader in skin cancer detection technology, has begun the process to obtain US Food and Drug Administration (FDA) approval for Verisante Aura
Rosetta Genomics Sells Ownership in Rosetta Green
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that it has entered into a Share Transfer Agreement with certain purchasers, pursuant to which it has sold all of the ordinary shares of Rosetta Green Ltd. ("Rosetta Green") it held. Prior to the transaction, Rosetta Genomics owned approximately 50
Soon, biosensors to detect lung cancer from exhaled breath
Scientists are developing biosensors capable of detecting the presence of tumour markers of lung cancer in exhaled breath.
Soybean compounds enhances effects of cancer radiotherapy
Compounds found in soybean compounds make radiation therapy to treat lung cancer tumours more effective, a new study has revealed.
Radiation therapy to become more effective and safer
Radiation therapy may soon have fewer side effects and doubled efficiency, a new study has revealed.
Now, breath test can detect, characterize lung cancer
A new breath test will now help in identifying and differentiating between the types of lung cancer in humans with high accuracy, a new study has suggested.
